Executive leadership from IDEXX Laboratories, Inc. (NASDAQ: IDXX)—led by Chief Executive Officer Mike Erickson and Chief Financial Officer Andrew Emerson—presented a comprehensive investor update at the Barclays 24th Annual Global Financial Services Conference and the Morgan Stanley 24th Annual Global Healthcare Conference.

Addressing institutional investors, management outlined a strategic framework designed to insulate long-term financial performance from near-term macroeconomic headwinds. While acknowledging a 1.5% to 2.0% projected decline in veterinary clinical visits across key markets in the second half of the year, IDEXX reiterated its long-term targets of >10% organic revenue growth and >15% EPS growth, backed by operating margins targeted to exceed 32%.

1. Expanding Diagnostic Utilization & Analyzer Installed Base

IDEXX highlighted that veterinary diagnostics remain significantly underpenetrated globally, with routine blood work performed in only ~20% of standard veterinary clinical visits. Management emphasized that expanding testing scope per visit provides a durable buffer against fluctuating practice traffic.

• Next-Gen Analyzer Platforms: Key growth drivers include the rapid clinical adoption of the IDEXX inVue Dx™ slide-free cellular analyzer and ongoing expansion of the core Catalyst™ (chemistry) and ProCyte™ (hematology) point-of-care ecosystem.

• Oncology & Specialty Diagnostics: The rollout of IDEXX Cancer Dx™ (initially targeting lymphoma, with planned panel expansions to cover mast cell tumors and hemangiosarcoma) targets an underserved market of 25 million at-risk dogs worldwide.

• Aging Pet Demographics: Post-pandemic pet demographics show 8 to 9 million more medicalized pets and an average 12% increase in canine/feline lifespan over the past decade. Older pets translate to a >16% gain in lifetime diagnostic value per animal.

2. Software Integration, AI, & Enterprise Efficiency

IDEXX’s technology roadmap focuses on merging workflow software with artificial intelligence to optimize clinical practice operations and lower cost structures.

• Software & Telehealth Ecosystem: Rapid adoption of cloud-native Practice Information Management Systems (PIMS)—such as ezyVet—has streamlined clinical workflows, allowing veterinary teams to integrate diagnostic orders directly with digital patient charts.

• AI-Driven Clinical Interpretation: Machine learning models are being deployed across veterinary radiology and cytology imaging services, accelerating reference-lab turnaround times and delivering automated preliminary insights.

• US$50M Efficiency Roadmap: Through internally generated operational efficiencies and AI-driven automation, IDEXX projects US$50 million in structural cost savings by 2027, allowing the firm to self-fund the majority of its R&D and commercial expansion initiatives without issuing new capital debt or dilutive equity.

3. Commercial Expansion & Emerging Channels

To accelerate penetration outside North America, IDEXX is deploying targeted commercial investments across high-growth international geographies:

• Emerging Geographic Growth: The company reported strong double-digit international growth in Companion Animal Group (CAG) Diagnostics recurring revenue, led by expanded field sales coverage across Latin America and the Asia-Pacific region.

• Direct-to-Consumer & Preventive Care: IDEXX is tapping into evolving pet-parent behaviors by supporting wellness testing, proactive screening, and direct digital integration that empowers pet owners to review lab results alongside their primary care veterinarian.